Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8381433 | 0.85 | L3MBTL1 (0.51) | KMT2AMEN1ALDH1A1PTGDR2 | |
| SCHEMBL6672033 | 0.79 | KMT2A (0.41) | KMT2AMEN1ALDH1A1PKMGAA | |
| SCHEMBL6674648 | 0.79 | KMT2A (0.41) | KMT2AMEN1ALDH1A1PKMHPGD | |
| SCHEMBL7605167 | 0.78 | KMT2A (0.40) | KMT2AMEN1ALDH1A1PKMGAA | |
| SCHEMBL7605169 | 0.78 | KMT2A (0.40) | KMT2AMEN1ALDH1A1PKMGAA | |
| SCHEMBL7609455 | 0.78 | KMT2A (0.40) | KMT2AMEN1ALDH1A1PKMGAA | |
| SCHEMBL7610455 | 0.77 | KMT2A (0.40) | KMT2AMEN1ALDH1A1PKMGAA | |
| SCHEMBL8378733 | 0.76 | ACHE (0.47) | KMT2AMEN1ALDH1A1GAAHPGD | |
| SCHEMBL4644614 | 0.76 | ITGB1 (0.58) | KMT2AMEN1ALDH1A1HPGDHSD11B1 | |
| SCHEMBL7606453 | 0.73 | TSHR (0.38) | KMT2AMEN1ALDH1A1PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605933-A4 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5- METHYL-N-CYCLOALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH ARYL AMINES | DU PONT (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1605933-A1 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5- METHYL-N-CYCLOALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH ARYL AMINES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-21 | — | — | EP | disclosed |
| US-6903222-B2 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-cycloalkyl-2-pyrrolidone by reductive amination of levulinic acid with aryl amines | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| WO-2004084887-A1 | PRODUCTION OF 5-METHYL-N-ARYL-2-PYRROLIDONE AND 5- METHYL-N-CYCLOALKYL-2-PYRROLIDONE BY REDUCTIVE AMINATION OF LEVULINIC ACID WITH ARYL AMINES | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192939-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-cycloalkyl-2-pyrrolidone by reductive amination of levulinic acid with aryl amines | MANZER LEO ERNEST (US) | 2004-09-30 | — | — | US | disclosed |
| US-6743819-B1 | METAL CATALYST | E. I. DU PONTE DE NEMOURS AND COMPANY | 2004-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192939-A1 | Production of 5-methyl-N-aryl-2-pyrrolidone and 5-methyl-N-cycloalkyl-2-pyrrolidone by reductive amination of levulinic acid with aryl amines | PNPO, ASNS, PAH | KMT2A 328/4885MEN1 3371/4885ALDH1A1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.